Biogen hit with Italian antitrust probe over multiple sclerosis market
MLex Summary: US pharma company Biogen is the target of an Italian antitrust probe into alleged efforts to shield its blockbuster multiple-sclerosis treatment from biosimilar competition. Investigators say Biogen is refusing...To view the full article, register now.
Already a subscriber? Click here to view full article